title: Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.
abstract: N-{4-[(2-Amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3- d]pyrimidin-5-yl)sulfanyl]benzoyl}-L-glutamic acid (4) and nine nonclassical analogues 5-13 were synthesized as potential dual thymidylate synthase (TS) and dihydrofolate reductase (DHFR) inhibitors. The key intermediate in the synthesis was 2-amino-6-methylthieno[2,3-d]pyrimidin-4(3 H)-one (16), which was converted to the 5-bromo-substituted compound 17 followed by an Ullmann reaction to afford 5-13. The classical analogue 4 was synthesized by coupling the benzoic acid derivative 19 with diethyl L-glutamate and saponification. Compound 4 is the most potent dual inhibitor of human TS (IC 50 = 40 nM) and human DHFR (IC 50 = 20 nM) known to date. The nonclassical analogues 5- 13 were moderately potent against human TS with IC 50 values ranging from 0.11 to 4.6 microM. The 4-nitrophenyl analogue 7 was the most potent compound in the nonclassical series, demonstrating potent dual inhibitory activities against human TS and DHFR. This study indicated that the 5-substituted 2-amino-4-oxo-6-methylthieno[2,3-d]pyrimidine scaffold is highly conducive to dual human TS-DHFR inhibitory activity.
authors.affiliation: Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, USA. gangjee@duq.edu
authors.forename: Aleem
authors.initials: A
authors.lastname: Gangjee
authors.forename: Yibin
authors.initials: Y
authors.lastname: Qiu
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Roy L
authors.initials: RL
authors.lastname: Kisliuk
mesh_terms: D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D005493:Folic Acid Antagonists / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008958:Models, Molecular; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology*; D013762:Tetrahydrofolate Dehydrogenase / Q000187:drug effects*; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors*
chemical_list: D004791:Enzyme Inhibitors; D005493:Folic Acid Antagonists; D011743:Pyrimidines; D013762:Tetrahydrofolate Dehydrogenase; D013940:Thymidylate Synthase
references.citation: J Med Chem. 1992 Nov 13;35(23):4450-4
references.pmid: 1447744
references.citation: Acta Crystallogr D Biol Crystallogr. 1997 Nov 1;53(Pt 6):638-49
references.pmid: 15299851
references.citation: J Med Chem. 1977 Nov;20(11):1531-3
references.pmid: 410932
references.citation: Cancer Res. 1991 Oct 15;51(20):5579-86
references.pmid: 1913676
references.citation: J Biol Chem. 1999 Apr 9;274(15):10388-94
references.pmid: 10187828
references.citation: Biochem Pharmacol. 1991 Oct 24;42(10):1885-95
references.pmid: 1741766
references.citation: Biochemistry. 1990 Oct 9;29(40):9467-79
references.pmid: 2248959
references.citation: Anticancer Agents Med Chem. 2008 Feb;8(2):205-31
references.pmid: 18288923
references.citation: J Med Chem. 1993 Oct 15;36(21):3103-12
references.pmid: 8230096
references.citation: J Med Chem. 1993 Mar 19;36(6):733-46
references.pmid: 8459400
references.citation: Ann Intern Med. 1984 May;100(5):663-71
references.pmid: 6231873
references.citation: Biochem Pharmacol. 1993 Feb 24;45(4):863-9
references.pmid: 7680860
references.citation: J Infect Dis. 1990 May;161(5):858-64
references.pmid: 2182728
references.citation: J Med Chem. 1996 Nov 8;39(23):4563-8
references.pmid: 8917644
references.citation: Drugs. 1997 Jan;53(1):40-73
references.pmid: 9010648
references.citation: J Biol Chem. 1962 Dec;237:3794-801
references.pmid: 13998281
references.citation: Anticancer Agents Med Chem. 2007 Sep;7(5):524-42
references.pmid: 17896913
references.citation: J Med Chem. 1995 Oct 27;38(22):4495-502
references.pmid: 7473577
references.citation: J Med Chem. 2004 Dec 30;47(27):6730-9
references.pmid: 15615522
references.citation: J Med Chem. 1973 Mar;16(3):185-8
references.pmid: 4632693
references.citation: J Med Chem. 1991 Feb;34(2):479-85
references.pmid: 1995868
references.citation: Biochemistry. 1997 Jan 21;36(3):586-603
references.pmid: 9012674
references.citation: Biochem Pharmacol. 2006 Mar 30;71(7):941-8
references.pmid: 16359642
references.citation: Semin Oncol. 1999 Apr;26(2 Suppl 6):42-7
references.pmid: 10598554
references.citation: J Biol Chem. 1980 Jun 25;255(12):5776-88
references.pmid: 6892914
references.citation: Biochem Pharmacol. 1988 Nov 1;37(21):4047-54
references.pmid: 2461200
references.citation: Curr Med Chem. 2006;13(4):377-98
references.pmid: 16475929
references.citation: Prog Med Chem. 1989;26:1-252
references.pmid: 2690183
references.citation: Cancer Res. 1997 Mar 15;57(6):1116-23
references.pmid: 9067281
references.citation: Curr Pharm Des. 2007;13(6):609-39
references.pmid: 17346178
references.citation: J Biol Chem. 1991 Apr 5;266(10):6181-7
references.pmid: 2007575
references.citation: J Med Chem. 1973 Mar;16(3):191-4
references.pmid: 4632695
references.citation: J Med Chem. 2008 Jan 10;51(1):68-76
references.pmid: 18072727
references.citation: J Med Chem. 2000 Oct 19;43(21):3837-51
references.pmid: 11052789
references.citation: Cancer Surv. 1986;5(1):47-79
references.pmid: 3297313